Neurobit
Entrepreneur First '18Singapore, SG · Founded 2018 · 1 known investors
Neurobit analyzes physiological signals recorded during sleep to identify patterns associated with cardiovascular disease, stroke, and dementia risk. Its AI models are trained on more than a trillion data points of multi-channel physiological data and are designed to work across different devices, signal types, and patient populations. The company's aim is a health analytics platform that treats sleep as a general-purpose biomarker for clinicians and researchers.
Also known as Neurobit Health · Neurobit Inc. · Neurobit Innovations · Neurobit Technologies
Founders & leadership
Neurobit was founded in 2018 by Kishan and Amiya Patanaik.
Investors · 1
Company profile
researched Aug 2026Neurobit is a health analytics company applying machine learning to physiological signals recorded during sleep, positioning sleep as a biomarker for predictive precision medicine. Its stated mission is a universal health analytics system usable by both healthcare providers and patients, with a focus on making care faster, more affordable and more accessible.
The company markets a product portfolio spanning research, clinical workflow and consumer sleep segments: Neurobit Research, Neurobit Hub, Neurobit Score and NDHL for research use; Neurobit PSG and Z3Pulse for clinical workflows; and SleepFit 360 and Neurobit Zen as sleep solutions. Neurobit PSG is an automatic polysomnography scoring system that has been the subject of benchmarking research in populations with suspected sleep disorders; other published work covers an automated heart-rate-based algorithm for sleep stage classification validated against conventional polysomnography and a wearable ECG device. A third-party directory characterises the company as a digital health company applying a suite of AI services to sleep healthcare and fitness.
Note on name twins: sources describing Neurobit Technologies Co., Ltd. (neurobittech.com, eye-movement and oculomotor diagnostics, Taiwan-based management team) and Neurobit Systems (neurobitsystems.com, neurofeedback/biofeedback hardware) refer to different companies and were excluded, other than the Singapore entity name "Neurobit Technologies" used by this company.
Founding story
Public sources describe Neurobit as co-founded by Amiya Patanaik and Kishan.
Business model
Neurobit sells software products and analytics services to institutional customers — sleep clinics, hospitals, universities and R&D centres — across research, clinical workflow and consumer sleep product lines, and partners with hardware vendors such as Movesense and Nonin whose devices its algorithms process.
Not specified in the sources beyond sales of software products and analytics services to healthcare and research institutions.
Traction
Over 150 universities, hospitals and R&D centres are stated to use the company's technology; peer-reviewed benchmarking and validation publications exist for its scoring algorithms; a third-party directory reports $1.6M in funding.
Latest developments
As of its investor page, Neurobit described itself as at an inflection point pending FDA clearance for Neurobit PSG and first-of-its-kind AASM AI accreditation, targeting adoption at at least 175 clinics in the first year after clearance. It was raising a bridge round through a special roll-up vehicle, with a first crowdfunding tranche scheduled to close 31 March 2024 and a Series A planned for Q2 2024. The site carries a 2026 copyright notice.
▸Full profile — market position, technology, go-to-market, geography, history, risks & controversies
Market position
Neurobit positions itself as an AI provider for sleep scoring and sleep-derived health analytics, citing use by over 150 universities, hospitals and R&D centres worldwide. A third-party medical startup directory lists Peloton, Whoop and CureFit as competitors and total funding of $1.6M.
Technology
AI and machine-learning models applied to multi-channel physiological signals, including automatic polysomnography scoring (Neurobit PSG) and heart-rate-based sleep stage classification validated against conventional polysomnography and a wearable ECG device; algorithms are exposed through SDKs and APIs for integration with third-party sensors such as Movesense.
Go-to-market
The company markets directly to healthcare institutions and research organisations, supported by peer-reviewed validation publications, device-maker partnerships (Movesense, Nonin) that expose SDK/API integrations, conference and webinar activity, and an Ignite program; commercial expansion is tied to obtaining FDA clearance and AASM AI accreditation for its autoscoring software.
Sleep clinics and checkup centres, hospitals and medical centres, universities and R&D institutions, healthcare providers, and end patients/consumers via sleep products.
Geography
Offices listed in New York, Singapore and Bengaluru; the corporate structure spans Neurobit Health (New York), Neurobit Innovations (Bangalore) and Neurobit Technologies (Singapore). Customers are described as spread worldwide.
History
Public sources indicate the company operates through multiple national entities: Neurobit Health (New York, USA), Neurobit Innovations (Bangalore, India) and Neurobit Technologies (Singapore). By 2021 its algorithms were featured in Movesense-powered projects for sleep apnea and sleep stage monitoring. In 2023-2024 it published validation research on its automatic scoring system, launched Neurobit HUB, and set out a roadmap of FDA submission and AASM AI certification in Q1 2024, FDA approval and a Series A in Q2 2024, followed by commercial scaling.
Risks & controversies
Key milestones described by the company — FDA clearance for Neurobit PSG and AASM AI accreditation — were stated as pending at the time of the investor page, and the roadmap dates are forward-looking targets rather than confirmed outcomes; no source confirms they were achieved. Reported funding is small ($1.6M per a third-party directory) relative to the planned commercial scale-up, and the company was raising a bridge round. The investor page also contains placeholder (lorem ipsum) text.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 5
launches, deals, and filingsCompany stated it was actively raising a bridge round through a special roll-up vehicle (RUV), with the first round of crowdfunding scheduled to close on 31 March 2024. A Series A was listed on the roadmap for Q2 2024. Amounts not disclosed.
Press release announcing Neurobit HUB, described as a tool for streamlining sleep and population health research.
Neurobit listed as monitoring sleep apnea and sleep stages with Movesense, with SDK and API available; featured among Movesense-powered projects of 2021. Movesense and Nonin are listed as partners.
Roadmap item for first-of-its-kind AI accreditation of autoscoring software for sleep stage accuracy by the AASM.
Company roadmap lists an FDA submission for its Neurobit PSG automatic polysomnography scoring product in Q1 2024, with FDA approval targeted for Q2 2024.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Neurobit Technologies - Homeneurobittech.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Neurobit do?
- Neurobit builds AI sleep-analytics software that uses sleep physiology as a biomarker for clinical and research use.
- Who founded Neurobit?
- Neurobit was founded by Kishan, Amiya Patanaik in 2018.
- Who are Neurobit's investors?
- Neurobit's investors include Entrepreneur First.
- Where is Neurobit headquartered?
- Neurobit is headquartered in Singapore, SG.